Please assess the completion status of the following clinical trial:

Trial Title: Dose-effect Relationship of Low-dose IL-2 in Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Age \[18-50\] years;~* With a T1D:~* Treated with insulin for ≤ 2 years,~* With at least one auto-antibody among: anti-islet, anti-GAD, anti-IA2, anti-ZnT8 ;~* No clinically relevant abnormal value for hematology, biochemistry, liver and kidney function~* Lymphocyte \[1000-4000\]/ mm3~* Informed consent signed by the patient and the investigator before any intervention necessary for the trial.~Exclusion Criteria:~* Contra-indications to IL2 :~* Hypersensibility to IL-2 or its excipients,~* Severe cardiopathy~* Ongoing infection requiring antibiotherapy,~* O2 Saturation ≤ 90 %~* Severe impairment of a vital organ~* Previous organ allograft~* Non authorized concomitant treatment : i.e. immuno-modulators, cytotoxic, drug modifying glycemia~* Cancer progressing or cured for less than 5 years except for primary basal cell carcinoma or carcinoma in situ of the uterine cervix.~* Participation to another clinical investigation in \< 3 months~* Pregnant or lactating women~* Male or female in age of procreation without efficient contraception during the study~* No affiliation to National Health Insurance

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- IL2-4 (Type: PLACEBO_COMPARATOR): None
- IL2-2 (Type: EXPERIMENTAL): 1 millions IU of IL-2 per day
- IL2-3 (Type: EXPERIMENTAL): 3 millions IU of IL-2 per day
- IL2-1 (Type: EXPERIMENTAL): 0.33 millions IU of IL-2 per day

Based on this trial design, predict the completion outcome and termination type (if applicable).